Development asset linked to Gedeon Richter Australia in public FDA and regional records.
pharma
Gedeon Richter Australia
Gedeon Richter Australia Pty Ltd
Gedeon Richter Australia drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
North Sydney, AU HQ
27 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- North Sydney, AU
- Employees
- 27
- Programs
- 1
- Drugs
- 5
- Patents
- 0
Gedeon Richter Australia pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Gedeon Richter Australia drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Gedeon Richter Australia in public FDA and regional records.
-
Development asset linked to Gedeon Richter Australia in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic.
- Mechanism
- Diagnostic
-
teriparatide
Systemic hormonal preparations (H05)US regulatory status: approved. Molecular target: Parathyroid hormone/parathyroid hormone-related peptide receptor.
- Target
- Parathyroid hormone/parathyroid hormone-related peptide receptor
- Mechanism
- Parathyroid hormone receptor agonist